FDA approves octaplas LG (Octapharma) coagulation factor

The FDA has on 18 January 2013, approved octaplas,from Octapharma, a pooled plasma (human) blood product for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels. Clotting protein deficiencies can cause excessive bleeding or excessive clotting.

Octaplas has been used extensively in Europe and other countries. A previous generation of octaplas was first marketed in 1992, and the current version has been marketed since 2006. All generations of the product have had similar manufacturing processes and comparable ingredients and properties. In total, more than 2 million patients have been treated with over 7 million doses of octaplas outside of the United States.